Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiosolutions raises $7m in series A:

This article was originally published in Clinica

Executive Summary

Heart repair specialist Cardiosolutions has secured $7m in a series A convertible preferred stock financing round. The financing, led by BioVentures Investors, will help Cardiosolutions fund the first human trials of its minimally-invasive system for treating mitral regurgitation, which are expected in 2008. The Stoughton, Massachusetts-based firm believes that its percuntaneous technologies - comprising the Spacer-Tek, the Percu-Pro, and the Mitra-Spacer - reduce patient discomfort and recovery time, as it avoids the need for open heart surgery. Mitral regurgitation is a heart valve disorder which affects approximately 6% of women and 3% of men, according to Cardiosolutions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel